Works about CANAGLIFLOZIN
Results: 679
New pharmacological approaches to diabetes management.
- Published in:
- Practice Nursing, 2015, v. 26, n. 3, p. 140, doi. 10.12968/pnur.2015.26.3.140
- By:
- Publication type:
- Article
Canagliflozin Pretreatment Attenuates Myocardial Dysfunction and Improves Postcardiac Arrest Outcomes After Cardiac Arrest and Cardiopulmonary Resuscitation in Mice.
- Published in:
- Cardiovascular Drugs & Therapy, 2024, v. 38, n. 2, p. 279, doi. 10.1007/s10557-022-07419-8
- By:
- Publication type:
- Article
Sodium-Glucose Co-transporter 2 Inhibitors Versus Metformin as the First-Line Treatment for Type 2 Diabetes: Is It Time for a Revolution?
- Published in:
- Cardiovascular Drugs & Therapy, 2023, v. 37, n. 2, p. 315, doi. 10.1007/s10557-021-07249-0
- By:
- Publication type:
- Article
Novel Anti-inflammatory Effects of Canagliflozin Involving Hexokinase II in Lipopolysaccharide-Stimulated Human Coronary Artery Endothelial Cells.
- Published in:
- Cardiovascular Drugs & Therapy, 2021, v. 35, n. 6, p. 1083, doi. 10.1007/s10557-020-07083-w
- By:
- Publication type:
- Article
Canagliflozin protects the cardiovascular system through effects on the gut environment in non-diabetic nephrectomized rats.
- Published in:
- Clinical & Experimental Nephrology, 2023, v. 27, n. 4, p. 295, doi. 10.1007/s10157-022-02312-y
- By:
- Publication type:
- Article
SGLT2 inhibition and three urological cancers: Up‐to‐date results.
- Published in:
- Diabetes/Metabolism Research & Reviews, 2024, v. 40, n. 3, p. 1, doi. 10.1002/dmrr.3797
- By:
- Publication type:
- Article
Comparative effectiveness of dapagliflozin vs DPP‐4 inhibitors on a composite endpoint of HbA1c, body weight and blood pressure reduction in the real world.
- Published in:
- Diabetes/Metabolism Research & Reviews, 2021, v. 37, n. 1, p. 1, doi. 10.1002/dmrr.3353
- By:
- Publication type:
- Article
The effects of canagliflozin compared to sitagliptin on cardiorespiratory fitness in type 2 diabetes mellitus and heart failure with reduced ejection fraction: The CANA-HF study.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Effects of SGLT2 inhibitors on fractures and bone mineral density in type 2 diabetes: An updated meta-analysis.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Effects of sodium-glucose cotransporter (SGLT) inhibitors in addition to insulin therapy on glucose control and safety outcomes in adults with type 1 diabetes: A meta-analysis of randomized controlled trials.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Sodium glucose cotransporter 2 inhibitors and gout risk: a sequence symmetry analysis.
- Published in:
- Clinical Rheumatology, 2023, v. 42, n. 9, p. 2469, doi. 10.1007/s10067-023-06647-z
- By:
- Publication type:
- Article
Development and Validation of a Stability-Indicating HPLC-DAD Method for the Determination of Canagliflozin and Metformin Simultaneously in Combination Dosage Form.
- Published in:
- Pharmaceutical Chemistry Journal, 2021, v. 55, n. 4, p. 402, doi. 10.1007/s11094-021-02436-7
- By:
- Publication type:
- Article
Canagliflozin Alleviates Atherosclerosis Progression through Inflammation, Oxidative Stress, and Autophagy in Western Diet-fed ApoE<sup>−/−</sup> Mice.
- Published in:
- Cardiovascular Innovations & Applications (CVIA), 2024, v. 9, p. 1, doi. 10.15212/CVIA.2023.0093
- By:
- Publication type:
- Article
Canagliflozin Regulates Ferroptosis, Potentially via Activating AMPK/PGC-1α/Nrf2 Signaling in HFpEF Rats.
- Published in:
- Cardiovascular Innovations & Applications (CVIA), 2022, v. 7, n. 1, p. 1, doi. 10.15212/CVIA.2022.0024
- By:
- Publication type:
- Article
A study of canagliflozin on post prandial blood sugar control.
- Published in:
- Indian Journal of Basic & Applied Medical Research, 2021, v. 10, n. 3, p. 18, doi. 10.36848/IJBAMR/2020/29215.55560
- By:
- Publication type:
- Article
SGLT2 inhibitors: Indications, doses and licences in adults.
- Published in:
- Diabetes & Primary Care, 2023, v. 25, n. 1, p. 9
- Publication type:
- Article
SGLT2 inhibitors: Indications, doses and licences (England, Scotland and Wales).
- Published in:
- Diabetes & Primary Care, 2021, v. 23, n. 6, p. 175
- Publication type:
- Article
CREDENCE trial stopped early.
- Published in:
- Diabetes & Primary Care, 2018, v. 20, n. 3, p. 104
- By:
- Publication type:
- Article
OBSERVE-4D.
- Published in:
- Diabetes & Primary Care, 2018, v. 20, n. 3, p. 102
- By:
- Publication type:
- Article
Association of HDL/TG Ratio as an Insulin Resistance Marker with Various Levels of Fasting Blood Glucose.
- Published in:
- Medical Laboratory Journal, 2016, v. 10, n. 1, p. 50
- By:
- Publication type:
- Article
A Descriptive Study on the Efficacy and Safety of Sodium Glucose Co-Transporter 2 Inhibitors as Add on Therapy in Patients with Type 2 Diabetes.
- Published in:
- Malaysian Journal of Medicine & Health Sciences, 2023, v. 19, p. 20
- By:
- Publication type:
- Article
Potential cardiovascular benefits of canagliflozin compared with other diabetes drugs.
- Published in:
- Nursing Older People, 2018, v. 30, n. 3, p. 11, doi. 10.7748/nop.30.3.11.s8
- By:
- Publication type:
- Article
EFFECT OF CANAGLIFLOZIN ALONE AND IN COMBINATION WITH METFORMIN ON HORMONAL DERANGEMENTS AND ESTROUS CYCLE IN A POLYCYSTIC OVARY SYNDROME RAT MODEL.
- Published in:
- Khyber Medical University Journal, 2021, v. 13, n. 2, p. 76, doi. 10.35845/kmuj.2021.20602
- By:
- Publication type:
- Article
EFFECT OF CANAGLIFLOZIN ALONE AND IN COMBINATION WITH METFORMIN ON HORMONAL DERANGEMENTS AND ESTROUS CYCLE IN A POLYCYSTIC OVARY SYNDROME RAT MODEL.
- Published in:
- Khyber Medical University Journal, 2021, v. 13, n. 2, p. 76, doi. 10.35845/kmuj.2021.20602
- By:
- Publication type:
- Article
Assessment of the Anti-Allodynic and Anti-Hyperalgesic Efficacy of a Glycine Transporter 2 Inhibitor Relative to Pregabalin, Duloxetine and Indomethacin in a Rat Model of Cisplatin-Induced Peripheral Neuropathy.
- Published in:
- Biomolecules (2218-273X), 2021, v. 11, n. 7, p. 940, doi. 10.3390/biom11070940
- By:
- Publication type:
- Article
Efficacy and safety of sodium–glucose co‐transporter‐2 inhibitors in kidney transplant recipients with diabetes mellitus.
- Published in:
- Diabetic Medicine, 2024, v. 41, n. 8, p. 1, doi. 10.1111/dme.15383
- By:
- Publication type:
- Article
Canagliflozin or acarbose versus placebo to ameliorate post‐bariatric hypoglycaemia – The HypoBar I randomized clinical trial protocol.
- Published in:
- Diabetic Medicine, 2024, v. 41, n. 6, p. 1, doi. 10.1111/dme.15320
- By:
- Publication type:
- Article
The antidiabetic SGLT2 inhibitor canagliflozin reduces mitochondrial metabolism in a model of skeletal muscle insulin resistance.
- Published in:
- Diabetic Medicine, 2024, v. 41, n. 5, p. 1, doi. 10.1111/dme.15271
- By:
- Publication type:
- Article
Poster abstracts.
- Published in:
- Diabetic Medicine, 2024, v. 41, p. 1, doi. 10.1111/dme.15296
- Publication type:
- Article
Clinical practice guidelines for management of hyperglycaemia in adults with diabetic kidney disease.
- Published in:
- Diabetic Medicine, 2022, v. 39, n. 4, p. 1, doi. 10.1111/dme.14769
- By:
- Publication type:
- Article
Basic and clinical science posters: Vascular and endothelial function.
- Published in:
- Diabetic Medicine, 2021, v. 38, p. 1, doi. 10.1111/dme.22_14556
- Publication type:
- Article
Renal outcomes with the newer antidiabetes drugs: the era before and after CREDENCE.
- Published in:
- Diabetic Medicine, 2020, v. 37, n. 4, p. 593, doi. 10.1111/dme.14262
- By:
- Publication type:
- Article
SGLT2 inhibitors in Type 1 diabetes: is this the future?
- Published in:
- Diabetic Medicine, 2018, v. 35, n. 12, p. 1642, doi. 10.1111/dme.13791
- By:
- Publication type:
- Article
Unmasking and aggravation of polycythemia vera by canagliflozin.
- Published in:
- Diabetic Medicine, 2018, v. 35, n. 11, p. 1613, doi. 10.1111/dme.13706
- By:
- Publication type:
- Article
Glycaemic efficacy of canagliflozin is largely independent of baseline β-cell function or insulin sensitivity.
- Published in:
- Diabetic Medicine, 2016, v. 33, n. 12, p. 1744, doi. 10.1111/dme.13033
- By:
- Publication type:
- Article
Cost-Effectiveness of Canagliflozin Versus Dapagliflozin Added to Metformin in Patients With Type 2 Diabetes in China.
- Published in:
- Frontiers in Pharmacology, 2019, p. N.PAG, doi. 10.3389/fphar.2019.00480
- By:
- Publication type:
- Article
Canagliflozin Inhibits Human Endothelial Cell Proliferation and Tube Formation.
- Published in:
- Frontiers in Pharmacology, 2019, p. N.PAG, doi. 10.3389/fphar.2019.00362
- By:
- Publication type:
- Article
Fanconi syndrome associated with SGLT2 inhibitor, canagliflozin.
- Published in:
- 2018
- By:
- Publication type:
- Case Study
Cost-Effectiveness of SGLT2 Inhibitors in a Real-World Population: A MICADO Model-Based Analysis Using Routine Data from a GP Registry.
- Published in:
- PharmacoEconomics, 2023, v. 41, n. 10, p. 1249, doi. 10.1007/s40273-023-01286-3
- By:
- Publication type:
- Article
Canagliflozin on top of dual renin-angiotensin system blockade in a woman with partial acquired lipodystrophy, type 2 diabetes and severely proteinuric chronic kidney disease: a case report.
- Published in:
- Frontiers in Endocrinology, 2023, p. 1, doi. 10.3389/fendo.2023.1172468
- By:
- Publication type:
- Article
Evaluation of efficacy and safety of glucokinase activators--a systematic review and meta-analysis.
- Published in:
- Frontiers in Endocrinology, 2023, p. 1, doi. 10.3389/fendo.2023.1175198
- By:
- Publication type:
- Article
The impact of SGLT2 inhibitors on αKlotho in renal MDCK and HK-2 cells.
- Published in:
- Frontiers in Endocrinology, 2023, v. 14, p. 01, doi. 10.3389/fendo.2023.1069715
- By:
- Publication type:
- Article
Effect of sodium-glucose cotransporter protein-2 inhibitors on left ventricular hypertrophy in patients with type 2 diabetes: A systematic review and meta-analysis.
- Published in:
- Frontiers in Endocrinology, 2023, v. 13, p. 1, doi. 10.3389/fendo.2022.1088820
- By:
- Publication type:
- Article
Canagliflozin promotes osteoblastic MC3T3-E1 differentiation via AMPK/RUNX2 and improves bone microarchitecture in type 2 diabetic mice.
- Published in:
- Frontiers in Endocrinology, 2022, v. 13, p. 1, doi. 10.3389/fendo.2022.1081039
- By:
- Publication type:
- Article
Canagliflozin mitigates ferroptosis and improves myocardial oxidative stress in mice with diabetic cardiomyopathy.
- Published in:
- Frontiers in Endocrinology, 2022, v. 13, p. 1, doi. 10.3389/fendo.2022.1011669
- By:
- Publication type:
- Article
Influence of dipeptidyl peptidase-4 inhibitors on glycemic variability in patients with type 2 diabetes: A metaanalysis of randomized controlled trials.
- Published in:
- Frontiers in Endocrinology, 2022, v. 13, p. 1, doi. 10.3389/fendo.2022.935039
- By:
- Publication type:
- Article
Euglycemic Ketoacidosis in a Patient without Diabetes Taking Sodium-Glucose Cotransporter 2 Inhibitors for Heart Failure.
- Published in:
- 2024
- By:
- Publication type:
- Case Study
Exploring insulin alternatives: A new era in diabetes treatment.
- Published in:
- African Journal of Diabetes Medicine, 2024, v. 32, n. 5, p. 1, doi. 10.54931/AJDM-32.5.5
- By:
- Publication type:
- Article
Healthcare resource utilization and healthcare costs in patients with type 2 diabetes mellitus initiating sodium-glucose cotransporter 2 inhibitors vs dipeptidyl peptidase-4 inhibitors in Japan: A real-world administrative database analysis.
- Published in:
- Journal of Diabetes Investigation, 2024, v. 15, n. 3, p. 374, doi. 10.1111/jdi.14123
- By:
- Publication type:
- Article
Real‐world risk of cardiovascular diseases in patients with type 2 diabetes associated with sodium–glucose cotransporter 2 inhibitors in comparison with metformin: A propensity score‐matched model analysis in Japan.
- Published in:
- Journal of Diabetes Investigation, 2023, v. 14, n. 11, p. 1262, doi. 10.1111/jdi.14062
- By:
- Publication type:
- Article